Spyre Therapeutics, Inc. SYRE Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s accrued expenses and other liabilities?
- Spyre Therapeutics, Inc. (SYRE) reported accrued expenses and other liabilities of $29.16M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s accrued expenses and other liabilities changed year-over-year?
- Spyre Therapeutics, Inc.'s accrued expenses and other liabilities increased by 34.8% year-over-year, from $21.63M to $29.16M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s accrued expenses and other liabilities?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s accrued expenses and other liabilities has grown at a 14.2% compound annual growth rate (CAGR), from $13.87M to $26.95M.